rivaroxaban
UkraineDrugs containing this active substance
-
The drug is used for the prevention of venous thromboembolism in adults following hip or knee replacement surgery. It is also prescribed for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent their recurrence.
Form: tablets, film-coated
Active substance Dosage rivaroxaban 10 mg ATC: B01AF01
Manufacturer: Bayer AG (Production of bulk products, primary packaging, secondary packaging, batch control, batch release)
-
The drug is used for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation. It is also prescribed for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for the prevention of their recurrence. In children, it is used for the treatment and prevention of recurrences of venous thromboembolism (VTE).
Form: tablets, film-coated
Active substance Dosage rivaroxaban 15 mg ATC: B01AF01
Manufacturer: Bayer AG (manufacturing bulk products, primary packaging, secondary packaging, batch control, batch release)
-
The drug is used for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation. It is also prescribed for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for the prevention of their recurrence. In children, it is used for the treatment and prevention of recurrences of venous thromboembolism (VTE).
Form: tablets, film-coated
Active substance Dosage rivaroxaban 20 mg ATC: B01AF01
Manufacturer: Bayer AG (manufacturing bulk products, primary packaging, secondary packaging, batch control, batch release)
-
The drug is indicated for adults for the prevention of atherothrombotic events following acute coronary syndrome (ACS), as well as for patients with ischemic heart disease or peripheral artery disease with a high risk of ischemic complications.
Form: tablets, film-coated
Active substance Dosage rivaroxaban 2.5 mg ATC: B01AF01
Manufacturer: Bayer AG (for the entire manufacturing process)
-
The drug is used for the treatment of venous thromboembolism (VTE) and the prevention of its recurrence in children and adolescents (up to 18 years of age) following initial therapy with other anticoagulants.
Form: suspension, oral
Active substance Dosage rivaroxaban 1 mg/ml ATC: B01AF01
Manufacturer: Bayer AG (manufacturing in bulk, primary packaging, secondary packaging, quality control, batch release)